Repurposing of the RIPK1 selective benzo[1,4]oxazepin-4-one scaffold for the development of a type-III LIMK1/2 inhibitor
Sebastian Mandel(Goethe University Frankfurt), Stefan Knapp(Goethe University Frankfurt)
Cited by 2
Related Papers
Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
|Cell|2012|1.7k
The promise and peril of chemical probes
|Nature Chemical Biology|2015|848
Bromodomains as therapeutic targets
|Expert Reviews in Molecular Medicine|2011|436
Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers
|Cancer Research|2021|70
Preclinical target validation using patient-derived cells
|Nature Reviews Drug Discovery|2015|54